CoChat

Therapeutic Responses of Plasmodium vivax Malaria to Chloroquine and Primaquine Treatment in Northeastern Myanmar

Yuan, Lili, Wang, Ying, Parker, Daniel M., Gupta, Bhavna, Yang, Zhaoqing, Liu, Huaie, Fan, Qi, Cao, Yaming, Xiao, Yuping, Lee, Ming-chieh, Zhou, Guofa, Yan, Guiyun, Baird, J. Kevin, Cui, Liwang · 2015 · Antimicrobial Agents and Chemotherapy
Cited by 50

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Chloroquine-primaquine (CQ-PQ) continues to be the frontline therapy for radical cure of Plasmodium vivax malaria. Emergence of CQ-resistant (CQR) P. vivax parasites requires a shift to artemisinin combination therapies (ACTs), which imposes a significant financial, logistical, and safety burden. Monitoring the therapeutic efficacy of CQ is thus important. Here, we evaluated the therapeutic efficacy of CQ-PQ for P. vivax malaria in northeast Myanmar. We recruited 587 patients with P. vivax monoinfection attending local malaria clinics during 2012 to 2013. These patients received three daily doses of CQ at a total dose of 24 mg of base/kg of body weight and an 8-day PQ treatment (0.375 mg/kg/day) commencing at the same time as the first CQ dose. Of the 401 patients who finished the 28-day follow-up, the cumulative incidence of recurrent parasitemia was 5.20% (95% confidence interval [CI], 3.04% to 7.36%). Among 361 (61%) patients finishing a 42-day follow-up, the cumulative incidence of recurrent blood-stage infection reached 7.98% (95% CI, 5.20% to 10.76%). The cumulative risk of gametocyte carriage at days 28 and 42 was 2.21% (95% CI, 0.78% to 3.64%) and 3.93% (95% CI, 1.94% to 5.92%), respectively. Interestingly, for all 15 patients with recurrent gametocytemia, this was associated with concurrent asexual stages. Genotyping of recurrent parasites at the merozoite surface protein 3α gene locus from 12 patients with recurrent parasitemia within 28 days revealed that 10 of these were the same genotype as at day 0, suggesting recrudescence or relapse. Similar studies in 70 patients in the same area in 2007 showed no recurrent parasitemias within 28 days. The sensitivity to chloroquine of P. vivax in northeastern Myanmar may be deteriorating.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.04270-14

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 41

  1. 10.1371/journal.pntd.0001814 · DOI · Paper page
  2. 10.1016/S1473-3099(04)01043-6 · DOI · Paper page
  3. 10.4269/ajtmh.2007.77.79 · DOI · Paper page
  4. 10.1128/CMR.00008-09 · DOI · Paper page
  5. 10.1128/AAC.01296-10 · DOI
  6. 10.1016/S0140-6736(89)91792-3 · DOI · Paper page
  7. 10.1016/0035-9203(92)90531-G · DOI · Paper page
  8. 10.4269/ajtmh.1991.44.547 · DOI · Paper page
  9. 10.1093/infdis/164.1.222 · DOI
  10. 10.1056/NEJM199103283241317 · DOI
  11. 10.1016/S1473-3099(14)70855-2 · DOI · Paper page
  12. 10.1016/j.pt.2012.08.005 · DOI
  13. Delacollette C, D'Souza C, Christophel E, Thimasarn K, Abdur R, Bell D, Dai TC, Gopinath D, Lu S, Mendoza R, Ortega L, Rastogi R, Tantinimitkul C, Ehrenberg J. 2009. Malaria trends and challenges in the Greater Mekong Subregion. Southeast Asian J Trop Med Public Health 40:674–691.
  14. 10.1016/0035-9203(93)90294-Z · DOI
  15. 10.1016/0035-9203(95)90556-1 · DOI
  16. 10.1111/j.1365-3156.2007.01978.x · DOI
  17. 10.1186/1475-2875-12-361 · DOI
  18. 10.4269/ajtmh.1999.61.518 · DOI
  19. 10.4269/ajtmh.2003.68.613 · DOI
  20. 10.4269/ajtmh.1997.56.627 · doi:10.4269/ajtmh.1997.56.627
  21. 10.4269/ajtmh.2010.09-0428 · doi:10.4269/ajtmh.2010.09-0428
  22. 10.1093/infdis/169.4.932 · DOI
  23. 10.1016/j.bcp.2005.07.021 · doi:10.1016/j.bcp.2005.07.021
  24. Baird JK, Wiady I, Sutanihardja A, Suradi Purnomo Basri H, Sekartuti Ayomi E, Fryauff DJ, Hoffman SL. 2002. Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia. Am J Trop Med Hyg 66:659–660. · DOI
  25. 10.1093/infdis/171.6.1678 · DOI
  26. 10.1016/S0035-9203(99)90149-9 · DOI
  27. 10.1128/AAC.44.6.1680-1685.2000 · DOI · Paper page
  28. 10.1016/j.trstmh.2005.04.024 · DOI
  29. 10.1186/1475-2875-10-44 · DOI
  30. Vijaykadga S, Rojanawatsirivej C, Congpoung K, Wilairatana P, Satimai W, Uaekowitchai C, Pumborplub B, Sittimongkol S, Pinyorattanachote A, Prigchoo P. 2004. Assessment of therapeutic efficacy of chloroquine for vivax malaria in Thailand. Southeast Asian J Trop Med Public Health 35:566–569.
  31. Congpoung K, Satimai W, Sujariyakul A, Intanakom S, Harnpitakpong W, Pranuth Y, Cholpol S, Bualombai P. 2011. In vivo sensitivity monitoring of chloroquine for the treatment of uncomplicated vivax malaria in four bordered provinces of Thailand during 2009-2010. J Vector Borne Dis 48:190–196.
  32. 10.1186/1475-2875-13-364 · DOI
  33. 10.1093/cid/cir631 · DOI · Paper page
  34. Liang GL, Sun XD, Wang J, Zhang ZX. 2009. Sensitivity of Plasmodium vivax to chloroquine in Laza City, Myanmar. Chin J Parasitol Parasitic Dis 27:175–176. (In Chinese.)
  35. 10.1016/0140-6736(93)92568-E · DOI · Paper page
  36. 10.4269/ajtmh.2003.69.548 · doi:10.4269/ajtmh.2003.69.548
  37. 10.1155/2012/936067 · doi:10.1155/2012/936067
  38. 10.4269/ajtmh.2008.79.378 · DOI
  39. 10.1093/infdis/jit261 · DOI
  40. 10.1086/512241 · DOI · Paper page
  41. 10.1016/S1473-3099(10)70079-7 · DOI · Paper page

Cited by

See all 50

Metadata

Authors
Yuan, L., Wang, Y., Parker, D. M., Gupta, B., Yang, Z., Liu, H., Fan, Q., Cao, Y., Xiao, Y., Lee, M.-C., Zhou, G., Yan, G., Baird, J. K., & Cui, L.
Venue
Antimicrobial Agents and Chemotherapy
Published
2015-02
Volume
59
Issue
2
Pages
1230-1235
ISSN
  • 0066-4804
  • 1098-6596
Cited by
50
References
4
Language
en
Licence
journals.asm.org/non-commercial-tdm-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.